Kevin Lee Freeman Health Catalyst, Inc. (HCAT) insider trading activity

Kevin Lee Freeman is Chief Commercial Officer of Health Catalyst, Inc.. Currently has a direct ownership of 358,686 shares of HCAT, which is worth approximately $814,217. The most recent transaction as insider was on Dec 01, 2025, when has been sold 16,401 shares (Common Stock) at a price of $2.9 per share, resulting in proceeds of $47,562. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 359K

4.37% 3M change

51.38% 12M change

Total Value Held $814,217

Kevin Lee Freeman Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2025	SELL Payment of exercise price or tax liability	$47,562 $2.9 p/Share	16,401 Reduced 4.37%	358,686 Common Stock
Sep 02 2025	SELL Payment of exercise price or tax liability	$15,382 $3.36 p/Share	4,578 Reduced 1.21%	375,087 Common Stock
Jun 02 2025	SELL Payment of exercise price or tax liability	$17,231 $3.63 p/Share	4,747 Reduced 1.23%	379,665 Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$49,464 $4.58 p/Share	10,800 Reduced 2.73%	384,412 Common Stock
Feb 20 2025	BUY Grant, award, or other acquisition	-	158,262 Added 28.59%	395,212 Common Stock
Dec 02 2024	SELL Open market or private sale	$67,050 $8.94 p/Share	7,500 Reduced 3.07%	236,950 Common Stock
Dec 01 2024	SELL Payment of exercise price or tax liability	$102,536 $8.97 p/Share	11,431 Reduced 4.47%	244,450 Common Stock

Sep 03 2024	SELL Payment of exercise price or tax liability	$20,152 $7.27 p/Share	2,772 Reduced 1.04%	263,381 Common Stock
Sep 03 2024	SELL Open market or private sale	$54,150 $7.22 p/Share	7,500 Reduced 2.85%	255,881 Common Stock
Jun 11 2024	SELL Open market or private sale	$48,975 $6.53 p/Share	7,500 Reduced 2.74%	266,153 Common Stock
Jun 03 2024	SELL Payment of exercise price or tax liability	$19,270 $6.53 p/Share	2,951 Reduced 1.07%	273,653 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$36,547 $8.05 p/Share	4,540 Reduced 1.61%	276,604 Common Stock
Feb 20 2024	BUY Grant, award, or other acquisition	-	113,334 Added 28.73%	281,144 Common Stock
Dec 01 2023	SELL Payment of exercise price or tax liability	$21,761 $7.45 p/Share	2,921 Reduced 1.71%	167,810 Common Stock
Sep 01 2023	SELL Payment of exercise price or tax liability	$99,658 $11.78 p/Share	8,460 Reduced 4.72%	170,731 Common Stock
Jun 01 2023	SELL Payment of exercise price or tax liability	$11,667 $11.24 p/Share	1,038 Reduced 0.58%	179,191 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$22,421 $14.29 p/Share	1,569 Reduced 0.87%	177,846 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	3,083 Added 1.68%	180,929 Common Stock
Dec 01 2022	SELL Payment of exercise price or tax liability	$26,049 $10.65 p/Share	2,446 Reduced 1.34%	179,415 Common Stock
Sep 08 2022	BUY Grant, award, or other acquisition	-	120,000 Added 39.75%	181,861 Common Stock

KLF

Kevin Lee Freeman

Chief Commercial Officer

South Jordan, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HCAT shares.

Notify only if

Value

Insider Trading

Get notified when an Health Catalyst, Inc. insider buys or sells HCAT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Health Catalyst, Inc.

Track Activities on HCAT

Account